Pharmacological and clinical evaluation of the activity and tolerance of a new oral antidiabetic compound, glydiazinamide or K 4024.
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D001786:Blood Glucose; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D011719:Pyrazines; D013453:Sulfonylurea Compounds